FOLH1 and pachyonychia congenita: In men with mCRPC progressing after docetaxel in the TheraP/ANZUP 1603 clinical trial mentioned above (which evaluated [177Lu]Lu-PSMA-617 vs. cabazitaxel in mCRPC), SUVmean ≥ 10 in [68Ga]Ga-PSMA-11 imaging was predictive of a higher likelihood of favorable response to [177Lu]Lu-PSMA-617 than to cabazitaxel, whilst a high metabolic tumor burden on [18F]FDG PET (often found in PC with neuroendocrine features and possibly induced by glucose transporters overexpression [67]) was associated with a worse prognosis regardless of the randomly assigned treatment.